SIRT for Potentially Resectable HCC

Who May Qualify: - HCC with diagnosis confirmed pathologically or clinically - No pervious treatment for HCC - At least one measurable intrahepatic target lesion - Potentially resectable HCC: tumor(s) confined to the left/right hemiliver, with/without invasion to the unilateral branch of the portal vein and/or hepatic vein - Disease amenable to SIRT (after evaluation) - Child-Pugh Class A or without cirrhosis - Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 - Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA\<10\^3 IU/mL - Patients with hepatitis C need to finish the anti-HCV treatment - Adequate organ and bone marrow function; the blood biochemical examination: platelet count ≥75×10\^9/L, white blood cell count \>3.0×10\^9/L, absolute value of neutrophils \>1.5×10\^9/L, blood count (hemoglobin) at least 85 g/L, ASL and AST≤5×ULN, creatinine≤1.5×ULN, INR\<1.5 or PT/APTT normal range - expected to live at least 6 months Who Should NOT Join This Trial: - Tumor involving main portal vein, bilateral branches of portal vein, or vena cava - tumor extention beyond one lobe of the liver - Bilobar tumor distribution - Extrahepatic metastasis - Decompensated liver function, including ascites, bleeding from esophageal and gastric varices, and/or hepatic encephalopathy - Organ (heart, kidney) dysfunction - HBsAg and anti-HCV antibody positive concurrently - History of malignancy other than HCC - Uncontrolled infection - History of HIV - History of organ and cell transplantation - Patients with bleeding tendency Always talk to your doctor about whether this trial is right for you.